We have added the final short review of a recent study: carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. This is the last of three new, short studies published this month.
Independent commentary is provided by Associate Professor Cindy Lee, the clinical co-lead in the myeloma program at Royal Adelaide Hospital and The Queen Elizabeth Hospital, South Australia.
Please login below to download this issue (PDF)